<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="88">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05159999</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00012367</org_study_id>
    <secondary_id>R01DK123104</secondary_id>
    <nct_id>NCT05159999</nct_id>
  </id_info>
  <brief_title>The Home Blood Pressure (BP) Trial</brief_title>
  <acronym>Home-BP</acronym>
  <official_title>The Home Blood Pressure (BP) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main study will be a two arm 10-month, cross-over randomized controlled trial of 200&#xD;
      participants treated with end-stage-kidney-disease treated with in-center hemodialysis in the&#xD;
      Seattle and San Francisco area comparing a strategy of targeting home vs. pre-dialysis&#xD;
      systolic blood pressure &lt;140 mmHg to reduce rates of intradialytic hypotension. The target&#xD;
      systolic blood pressure of &lt;140 mmHg in both treatment groups will be achieved using an&#xD;
      algorithm of dry weight adjustment and anti-hypertensive medication adjustment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main study be a two arm 10-month, cross-over randomized controlled trial of 200&#xD;
      participants treated with in-center hemodialysis in the Seattle and San Francisco area&#xD;
      comparing a strategy of targeting home vs. pre-dialysis systolic blood pressure &lt;140 mmHg in&#xD;
      reducing rates of intradialytic hypotension. The target systolic blood pressure of 100-140&#xD;
      mmHg will be achieved using an algorithm of volume management and anti-hypertensive&#xD;
      medication adjustment every two weeks. Home blood pressure measures will be recorded&#xD;
      throughout via a mobile health blood pressure monitor over the 10-month study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intradialytic hypotension (IDH), defined as systolic blood pressure&lt;90 mmHg during dialysis</measure>
    <time_frame>10 months</time_frame>
    <description>Test the effect of treating home SBP &lt;140mmHg vs a pre-dialysis SBP &lt;140mmHg on rates of IDH</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatigue by SONG-HD Score</measure>
    <time_frame>10 months</time_frame>
    <description>Test the effect of treating home SBP &lt;140mmHg vs a pre-dialysis SBP &lt;140mmHg on patient reported fatigue, as ascertained by the SONG-HD Fatigue Score (PMID: 33093215)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cramping</measure>
    <time_frame>10 months</time_frame>
    <description>Test the effect of treating home SBP &lt;140mmHg vs a pre-dialysis SBP &lt;140mmHg on frequency of cramping</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of hospitalizations for cardiovascular events and volume overload</measure>
    <time_frame>10 months</time_frame>
    <description>Test the effect of treating home SBP &lt;140mmHg vs a pre-dialysis SBP &lt;140mmHg on rates of hospitalizations for cardiovascular events and volume overload</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between pre-dialysis and home SBP</measure>
    <time_frame>10 months</time_frame>
    <description>Evaluate the correlation between pre-dialysis and home SBP under different treatment strategies</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Separation of blood pressures</measure>
    <time_frame>2 months</time_frame>
    <description>Determine whether the intervention is able to achieve a home systolic blood pressure &lt;130mmHg in this optional study.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>End Stage Renal Disease on Dialysis</condition>
  <arm_group>
    <arm_group_label>Home Systolic Blood Pressure &lt;140 mmHg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take their home blood pressure two times per week (one in the morning and one in the evening) on non-dialysis days, ideally mid-week. Home blood pressures will be reviewed every two weeks and dry weight and medications adjusted accordingly to reach a home systolic blood pressure target of &lt;140 mmHg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-Dialysis Systolic Blood Pressure &lt;140 mmHg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will have their blood pressure taken by an automated blood pressure device by dialysis unit staff using regular dialysis unit equipment according to usual clinical care. Pre-dialysis blood pressures will be reviewed every two weeks and dry weight and medications adjusted accordingly to reach a pre-dialysis systolic blood pressure target of &lt;140 mmHg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Home Systolic Blood Pressure &lt;130 mmHg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This will be an optional, exploratory 2 month study at the end of the primary 10-month trial. Participants will take their home blood pressure two times per week (one in the morning and one in the evening) on non-dialysis days, ideally mid-week. Home blood pressures will be reviewed every two weeks and dry weight and medications adjusted accordingly to reach a home systolic blood pressure target of &lt;130 mmHg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dry weight target adjustment</intervention_name>
    <description>Target dry weight will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target.</description>
    <arm_group_label>Home Systolic Blood Pressure &lt;130 mmHg</arm_group_label>
    <arm_group_label>Home Systolic Blood Pressure &lt;140 mmHg</arm_group_label>
    <arm_group_label>Pre-Dialysis Systolic Blood Pressure &lt;140 mmHg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-hypertensive medications</intervention_name>
    <description>Anti-hypertensive medications will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target. Adjustment of currently prescribed anti-hypertensive medications will be prioritized before starting new medications. Only standard anti-hypertensive medications will be used, such as RAAS inhibitors, beta-blockers, calcium channel blockers and diuretics.</description>
    <arm_group_label>Home Systolic Blood Pressure &lt;130 mmHg</arm_group_label>
    <arm_group_label>Home Systolic Blood Pressure &lt;140 mmHg</arm_group_label>
    <arm_group_label>Pre-Dialysis Systolic Blood Pressure &lt;140 mmHg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years or older&#xD;
&#xD;
          -  Undergoing in-center, thrice weekly hemodialysis for treatment of end stage renal&#xD;
             disease (ESRD)&#xD;
&#xD;
          -  Greater than 3 months since initiation of dialysis&#xD;
&#xD;
          -  No anticipated change to peritoneal dialysis or kidney transplant within 10 months&#xD;
&#xD;
          -  Life expectancy greater than 10 months&#xD;
&#xD;
          -  Hypertension (defined as mean pre-dialysis SBP &gt; 140 mmHg over prior 2 weeks or taking&#xD;
             BP medications)&#xD;
&#xD;
          -  Able to obtain/measure a brachial blood pressure at dialysis and at home (e.g., no&#xD;
             left ventricular assist device, blood pressure not been taken routinely in lower&#xD;
             extremity at dialysis unit)&#xD;
&#xD;
          -  No condition that the primary nephrologist or PIs feel precludes participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Incarcerated or institutionalized (prohibits home blood pressure measurement)&#xD;
&#xD;
          -  Participating in another intervention study that may affect blood pressure&#xD;
&#xD;
          -  Pregnant or anticipated pregnancy or breastfeeding (as this will require increase to&#xD;
             more than three times a week dialysis and/or preclude use of some classes of blood&#xD;
             pressure medications)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nisha Bansal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chi-yuan Hsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nisha Bansal, MD</last_name>
    <phone>206-221-1801</phone>
    <email>nbansal@uw.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Tsing</last_name>
    <phone>206-616-5190</phone>
    <email>jtsing@uw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Chi-yuan Hsu</last_name>
      <phone>415-476-2173</phone>
      <email>chi-yuan.hsu@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Nisha Bansal, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 18, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Nisha Bansal</investigator_full_name>
    <investigator_title>Associate Professor, Division of Nephrology</investigator_title>
  </responsible_party>
  <keyword>Blood pressure, dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

